Portada›Miércoles 17 de diciembre de 2025
Biomédicas del NASDAQ ante la SEC, miércoles 17 de diciembre de 2025
Los 33 documentos que 27 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.
← martes 16 de diciembre de 2025 · jueves 18 de diciembre de 2025 →
El día, bloque a bloque
Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.
Emisiones y dilución
- AKTXAkari Therapeutics Plc424B5Nueva emisión de acciones con precioEDGAR
- IMNMImmunome Inc.424B5Nueva emisión de acciones con precioEDGAR
- KODKodiak Sciences Inc.424B5Nueva emisión de acciones con precioEDGAR
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 16, 2025, the closing sale price per warrant of our Public Warrants was $0.16. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 16, 2025, the closing sale price per warrant of our Public Warrants was $0.16. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 16, 2025, the closing sale price per warrant of our Public Warrants was $0.16. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
Participaciones y control
- CTORCITIUS ONCOLOGY, INC.SC 13D/ACambio en participación significativaEDGAR
- IRONDisc Medicine, Inc.SC 13D/ACambio en participación significativaEDGAR
- SVASINOVAC BIOTECH LTDSC 13D/ACambio en participación significativaEDGAR
- TNYATenaya Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
Informes y hechos relevantes
- AKTXAkari Therapeutics Plc8-KFin de acuerdo materialEDGAR
- LRMRLarimar Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
- VERUVERU INC.8-KResultadosEDGAR
En el documentoEl ensayo alcanzó su objetivo principaltexto original ▸
…PLATEAU clinical trial Efficacy The results for the 16 week active weight loss period of treatment with enobosarm 3 mg or placebo in combination with semaglutide: • The enobosarm 3 mg + semaglutide group met the primary endpoint of study, preservation of total lean mass, with a statistically significant 100% average preservation of total lean mass compared to placebo + semaglutide at 16 weeks. • Enobosarm + semaglutide treatment…
- YARWYarrow Bioscience, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
- ARDXARDELYX, INC.8-KCambio en el consejo o la direcciónEDGAR
- BMRNBIOMARIN PHARMACEUTICAL INC8-KCambio en el consejo o la direcciónEDGAR
- CNSPCNS Pharmaceuticals, Inc.8-KCambio en el consejo o la direcciónEDGAR
En el documentoCambio en la dirección de la empresatexto original ▸
…are no family relationships between Mr. Levin and any director or executive officer of the Company that would require disclosure under Item 401(d) of Regulation S-K. On December 16, 2025, John Climaco resigned from his positions as chief executive officer of CNS Pharmaceuticals, Inc. (the “Company”) and as a member of the Company’s Board of Directors, effective as of such date (the “Separation Date”). Mr. Climaco’s resignation as a member of the Company…
- COYACoya Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
- CRNXCrinetics Pharmaceuticals, Inc.8-KCambio en el consejo o la direcciónEDGAR
- FLNAFILANA THERAPEUTICS, INC.8-KCambio en el consejo o la direcciónEDGAR
- IMNMImmunome Inc.8-KOtros hechos relevantesEDGAR
- INSMINSMED Inc8-KOtros hechos relevantesEDGAR
- KLRSKalaris Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
- NAIINATURAL ALTERNATIVES INTERNATIONAL INC8-KNuevo acuerdo materialEDGAR
- SCLXScilex Holding Co8-KNuevo acuerdo materialEDGAR
- SGMTSagimet Biosciences Inc.8-KOtros hechos relevantesEDGAR
En el documentoAcuerdo de licencia o colaboracióntexto original ▸
…combination product containing denifanstat and resmetirom. The Company previously made a non-refundable up-front payment to TAPI in the amount of $2.5 million upon execution of a term sheet. Pursuant to the License Agreement, TAPI may be eligible to receive low single-digit royalties and potential additional manufacturing-related milestones of up to $5.5 million. The License Agreement terminates upon the date certain TAPI know-how ceases to be confidential information or the last…
- STROSUTRO BIOPHARMA, INC.8-KOtros hechos relevantesEDGAR
- TELOTelomir Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
- TENXTENAX THERAPEUTICS, INC.8-KOtros hechos relevantesEDGAR
- TRAWTraws Pharma, Inc.8-KOtros hechos relevantesEDGAR
- VERUVERU INC.10-KInforme anualEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…public accounting firm for the year ended September 30, 2025, includes an explanatory paragraph stating that our losses from operations and required additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern for a period of one year after the date the financial statements are issued. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will…
En el documentoContrasplit de accionestexto original ▸
…from “The Female Health Company” to “Veru Inc.” reflecting our focus on developing and commercializing biopharmaceutical products. 6 Table of Contents Reverse Stock Split On August 8, 2025, the Company effected a 1-for-10 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock. As a result of the Reverse Stock Split, each 10 shares of issued and outstanding common stock were automatically converted into…
- ZURAZura Bio Ltd8-KCambio en el consejo o la direcciónEDGAR
- ZVRAZEVRA THERAPEUTICS, INC.8-KCambio en el consejo o la direcciónEDGAR
← martes 16 de diciembre de 2025 · jueves 18 de diciembre de 2025 →
Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.